Go Pro
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel Free NIOX Stock Alerts

NIOX Group (NIOX) Competitors

NIOX Group logo
GBX 66.80 +0.80 (+1.21%)
As of 12:00 PM Eastern
Compare

NIOX vs. AMS, TSTL, EKF, SPEC, and CREO

Should you buy NIOX Group stock or one of its competitors? NIOX Group's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does NIOX Group compare to Advanced Medical Solutions Group?

NIOX Group (LON:NIOX) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

NIOX Group presently has a consensus price target of GBX 86, suggesting a potential upside of 28.74%. Advanced Medical Solutions Group has a consensus price target of GBX 278.33, suggesting a potential downside of 1.47%. Given NIOX Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe NIOX Group is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 0.9%. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, NIOX Group had 1 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 1.22 beat NIOX Group's score of 1.08 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company Overall Sentiment
NIOX Group Positive
Advanced Medical Solutions Group Positive

NIOX Group has a net margin of 14.74% compared to Advanced Medical Solutions Group's net margin of 1.58%. NIOX Group's return on equity of 10.01% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.74% 10.01% 3.95%
Advanced Medical Solutions Group 1.58%1.44%2.35%

NIOX Group has higher earnings, but lower revenue than Advanced Medical Solutions Group. NIOX Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£47.50M5.92£995.88M£1.6440.73
Advanced Medical Solutions Group£228.94M2.69£11.22M£4.5262.50

NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, suggesting that its share price is 30% less volatile than the broader market.

Summary

NIOX Group beats Advanced Medical Solutions Group on 11 of the 17 factors compared between the two stocks.

How does NIOX Group compare to Tristel?

Tristel (LON:TSTL) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.98£6.54M£16.2425.25
NIOX Group£47.50M5.92£995.88M£1.6440.73

In the previous week, Tristel and Tristel both had 1 articles in the media. NIOX Group's average media sentiment score of 1.08 beat Tristel's score of 0.00 indicating that NIOX Group is being referred to more favorably in the news media.

Company Overall Sentiment
Tristel Neutral
NIOX Group Positive

22.4% of Tristel shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tristel has a beta of 0.344, meaning that its stock price is 66% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 28.74%. Given NIOX Group's stronger consensus rating and higher probable upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
NIOX Group 14.74%10.01%3.95%

Summary

NIOX Group beats Tristel on 9 of the 17 factors compared between the two stocks.

How does NIOX Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

EKF Diagnostics presently has a consensus price target of GBX 35, indicating a potential upside of 42.28%. NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 28.74%. Given EKF Diagnostics' higher possible upside, equities research analysts clearly believe EKF Diagnostics is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has lower revenue, but higher earnings than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.35M2.05£4.68M£0.4752.34
NIOX Group£47.50M5.92£995.88M£1.6440.73

NIOX Group has a net margin of 14.74% compared to EKF Diagnostics' net margin of 4.86%. NIOX Group's return on equity of 10.01% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.86% 3.58% 5.27%
NIOX Group 14.74%10.01%3.95%

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 40.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, NIOX Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for EKF Diagnostics. NIOX Group's average media sentiment score of 1.08 beat EKF Diagnostics' score of 0.00 indicating that NIOX Group is being referred to more favorably in the news media.

Company Overall Sentiment
EKF Diagnostics Neutral
NIOX Group Positive

EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Summary

NIOX Group beats EKF Diagnostics on 8 of the 14 factors compared between the two stocks.

How does NIOX Group compare to INSPECS Group?

NIOX Group (LON:NIOX) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 0.2% of INSPECS Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NIOX Group has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its stock price is 60% more volatile than the broader market.

NIOX Group has a net margin of 14.74% compared to INSPECS Group's net margin of -0.52%. NIOX Group's return on equity of 10.01% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.74% 10.01% 3.95%
INSPECS Group -0.52%-1.19%0.45%

NIOX Group currently has a consensus target price of GBX 86, suggesting a potential upside of 28.74%. Given NIOX Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe NIOX Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, NIOX Group had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for NIOX Group and 0 mentions for INSPECS Group. NIOX Group's average media sentiment score of 1.08 beat INSPECS Group's score of 0.00 indicating that NIOX Group is being referred to more favorably in the media.

Company Overall Sentiment
NIOX Group Positive
INSPECS Group Neutral

NIOX Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£47.50M5.92£995.88M£1.6440.73
INSPECS Group£193.23M0.53-£4.11M-£9.40N/A

Summary

NIOX Group beats INSPECS Group on 13 of the 16 factors compared between the two stocks.

How does NIOX Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Creo Medical Group has a beta of 1.563854, meaning that its share price is 56% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, Creo Medical Group had 3 more articles in the media than NIOX Group. MarketBeat recorded 4 mentions for Creo Medical Group and 1 mentions for NIOX Group. NIOX Group's average media sentiment score of 1.08 beat Creo Medical Group's score of 0.46 indicating that NIOX Group is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
NIOX Group Positive

NIOX Group has a net margin of 14.74% compared to Creo Medical Group's net margin of -268.57%. NIOX Group's return on equity of 10.01% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group-268.57% -38.29% -20.09%
NIOX Group 14.74%10.01%3.95%

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Creo Medical Group currently has a consensus target price of GBX 40, suggesting a potential upside of 313.82%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 28.74%. Given Creo Medical Group's higher probable upside, analysts plainly believe Creo Medical Group is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M6.71-£25.04M£1.009.67
NIOX Group£47.50M5.92£995.88M£1.6440.73

Summary

NIOX Group beats Creo Medical Group on 10 of the 16 factors compared between the two stocks.

Get NIOX Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIOX vs. The Competition

Export
MetricNIOX GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£281.14M£5.42B£7.11B£2.80B
Dividend Yield2.36%1.80%2.53%6.18%
P/E Ratio40.7324.71274.44366.17
Price / Sales5.9268.35608.0189,425.29
Price / Cash11.2132.6877.3827.89
Price / Book3.705.7110.956.83
Net Income£995.88M£152.11M£3.50B£5.89B
7 Day Performance1.83%-2.05%-2.16%-0.75%
1 Month Performance-1.18%-5.34%-6.41%16.84%
1 Year Performance-9.73%2.83%8.85%16.40%

NIOX Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NIOX
NIOX Group
2.5336 of 5 stars		GBX 66.80
+1.2%		GBX 86
+28.7%		-10.8%£281.14M£47.50M40.7392
AMS
Advanced Medical Solutions Group
1.0284 of 5 stars		GBX 282
+0.2%		GBX 278.33
-1.3%		+25.1%£612.56M£228.94M62.3910
TSTL
Tristel
N/AGBX 395
flat		N/A+11.7%£189.89M£49.54M24.32208
EKF
EKF Diagnostics
N/AGBX 26
+1.2%		GBX 35
+34.6%		-17.4%£110.04M£51.35M55.32356
SPEC
INSPECS Group
N/AGBX 92
-4.2%		N/A+111.4%£104.81M£193.23MN/A1,673

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NIOX) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
The rich already moved their money
By the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Mar...
Parkview Capital Group | Sponsoredtc pixel
My next big call (under $1)
Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...
Crypto 101 Media | Sponsoredtc pixel
A new kind of civil war is coming after election day?
Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...
Stansberry Research | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
The SEC Just Opened The Floodgates…
The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...
StocksToTrade | Sponsoredtc pixel
The Flaw Your Financial Advisor Will Not Name
The U.S. government values its gold at $42 an ounce, a price set by Congress in 1973 and never updated. Gold t...
Monetary Gold | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel